Skip to main content
SpringerLink
Log in

Omalizumab and the treatment of allergic rhinitis

  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Anti-IgE therapy affects mechanisms in the allergic response that are IgE-dependent or IgE-mediated and common to both allergic asthma and allergic rhinitis. Clinical trials of omalizumab in the treatment of patients with allergic rhinitis or comorbid allergic rhinitis and moderate to severe allergic asthma have recorded significant reductions in symptom severity scores of both conditions. This novel therapy has increased the knowledge base concerning IgE-mediated allergic responses, and, in keeping with its actions established in the treatment of asthma, appears to be useful in the treatment of moderate to severe allergic rhinitis, as well.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Greisner WA 3rd, Settipane RJ, Settipane GA: Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Asthma Proc 1998, 19:185–188.

    Article  PubMed  Google Scholar 

  2. Chaplin DD: The immune system. Part 1: Overview of the immune response. J Allergy Clin Immunol 2003, 111(Pt 3):S442-S459.

    Article  PubMed  CAS  Google Scholar 

  3. Oettgen HC, Geha RS: Molecular mechanisms in allergy and clinical immunology: IgE regulation and roles in asthma pathogenesis. J Allergy Clin Immunol 2001, 107:429–440.

    Article  PubMed  CAS  Google Scholar 

  4. Sheikh J: Rhinitis, Allergic. EMedicine Specialties-Allergy and Immunology. Edited by Kishyama JL, Talavera F, Dreskin SC, et al. EMedicineficom. October 23, 2002. Available at http:// www.emedicine.com/MED/topic104.htm. Accessed 10-29-03.

  5. Prussin C, Metcalf DD: The immune system. Part 4: IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003, 111(Pt 3):S486-S494.

    Article  PubMed  CAS  Google Scholar 

  6. Boniface S, Magnan A: Pathophysiology of the IgE-dependent reaction in respiratory allergy [English abstract; article in French]. Rev Pneumol Clin 2003, 59(Pt 1):77–83.

    PubMed  CAS  Google Scholar 

  7. Anand MK, Routes JM: Hypersensitivity reactions, immediate. In EMedicine Specialties-Allergy and Immunology. Edited by Lockey RF, Talavera F, Simon MR, et al. EMedicineficom. Nov 24, 2003. Available at http://www.emedicine.com/med/ topic1101.htm. Accessed 11-25-03

  8. Tilley SL, Hartney JM, Erikson CJ, et al.: Receptors and pathways mediating the effects of prostaglandin E2 on airway tone. Am J Physiol Lung Cell Mol Physiol 2003, 284:L599-L606. Epub 2002, Dec 13.

    PubMed  CAS  Google Scholar 

  9. Berger WE: Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease. Ann Allergy Asthma Immunol 2002, 88:152–160.

    Article  PubMed  CAS  Google Scholar 

  10. Casale TB: Experience with monoclonal antibodies in allergic-mediated disease: seasonal allergic rhinitis. J Allergy Clin Immunol 2001, 108:S84-S88. Review of the initial studies on anti-IgE and AR.

    Article  PubMed  CAS  Google Scholar 

  11. Beeh KM, Beier J, Kornmann O, et al.: A single nasal allergen challenge increases induced sputum inflammatory markers in non-asthmatic subjects with seasonal allergic rhinitis: correlation with plasma interleukin-5. Clin Exp Allergy 2003, 33:475–482.

    Article  PubMed  CAS  Google Scholar 

  12. Ponikau JU, Sherris DA, Kephart GM, et al.: Features of airway remodeling and eosinophilic inflammation in chronic rhinosinusitis: Is the histopathology similar to asthma? J Allergy Clin Immunol 2003, 112:877–882.

    Article  PubMed  Google Scholar 

  13. Lacroix JS, Potter EK: Nasonasal reflex mechanisms in anaesthetized dogs. Acta Otolaryngol 1999, 119:249–256.

    Article  PubMed  CAS  Google Scholar 

  14. Casale TB, Berstein IL, Busse WW, et al.: Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997, 100:110–121. The initial anti-IgE and AR study data directed subsequent studies to lower IgE to less than 50 ng/ml.

    Article  PubMed  CAS  Google Scholar 

  15. Xolair Prescribing Information. Novartis Pharmaceutical Corporation. June 2003. Available at http://www.gene.com/ gene/products/information/pdf/xolair-prescribing.pdf. Accessed 11-15-03.

  16. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25. BioDrugs 2002, 16:380-386.

  17. Busse W, Corren J, Lanier BQ, et al.: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001, 108:184–190. The US registration study that led to FDA approval of Xolair.

    Article  PubMed  CAS  Google Scholar 

  18. Soler M, Matz J, Townley R, et al.: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001, 18:254–261.

    Article  PubMed  CAS  Google Scholar 

  19. Casale TB, Condemi J, LaForce C, et al.: Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001, 286:2956–2967.

    Article  PubMed  CAS  Google Scholar 

  20. Busse W, Nayak A, Chervinsky P, et al.: Omalizumab (Xolair) improves perennial allergic rhinitis in patients who were previously unresponsive to treatment with nasal steroids or immunotherapy. J Allergy Clin Immunol 2001, 107(Pt 1):Abstracts 1 and 2.

  21. Adelroth E, Rak S, Haahtela T, et al.: Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000, 106:253–259.

    Article  PubMed  CAS  Google Scholar 

  22. Kuehr J, Brauburger J, Zielen S, et al.: Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002, 109:274–280. A fascinating study of SIT and Xolair.

    Article  PubMed  CAS  Google Scholar 

  23. Boulet LP, Canonica GW, Dahl R, et al.: Omalizumab, an anti-IgE antibody, provides parallel improvements in symptoms of allergic asthma and perennial allergic rhinitis in patients with both diseases: The SOLAR Study. Presented at Chest 2003, 69th Annual International Meeting of the American College of Chest Physicians, Orlando, FL: October 28, 2003. Chest 2003, 124 (Suppl):105S-a.

  24. Nayak A, Casale T, Miller SD, et al.: Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc 2003, 24:323–329.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Allergy and Asthma, 11160 Veirs Mill Road, Suite 414, 20902, Wheaton, MD, USA

    Michael A. Kaliner MD

Authors
  1. Michael A. Kaliner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaliner, M.A. Omalizumab and the treatment of allergic rhinitis. Curr Allergy Asthma Rep 4, 237–244 (2004). https://doi.org/10.1007/s11882-004-0032-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-004-0032-2

Keywords

Search

Navigation